Natraj Proteins Limited has announced the opening of a special window for re-lodgement of transfer requests for physical shares, following a recent SEBI circular. The company published newspaper advertisements on 17th March, 2026 in Free Press Journal English edition and Choutha Sansar Hindi edition to inform shareholders about this facility.

SEBI Circular Implementation

The special window has been established pursuant to SEBI Circular No. HO/38/13/11 (2) 2026-MIRSD-POD/1/3750/2026 dated 30th January, 2026. This regulatory directive specifically addresses the needs of shareholders who faced difficulties with their physical share transfer requests in the past.

Eligibility and Coverage

The special window is designed to accommodate two categories of physical share transactions:

• Physical shares that were sold or purchased prior to 1st April, 2019
• Transfer requests that were lodged prior to 1st April, 2019 but were subsequently rejected, returned, or not attended due to deficiencies in documents, processes, or other issues

Window Timeline

Submission Process

Shareholders seeking to utilize this facility must submit their transfer requests along with physical share certificates. All submissions should be made through the company's designated registrar and share transfer agent:

M/s Ankita Consultancy Pvt. Ltd.

• Address: 60, Electronic Complex, Pardeshipura, Indore (M.P.) 452010
• Telephone: 0731-4281333, 0731-4065799/97
• Fax: 0731-4065798
• Email: investor@ankitaiton.com

Company Communication

The announcement was signed by Kailash Chand Sharma, Chairman & Managing Director (DIN: 00012900), and communicated to BSE Limited on 17th March, 2026. The company has fulfilled its regulatory obligation by publishing the notice in both English and Hindi newspapers to ensure maximum reach among shareholders.

This initiative provides eligible shareholders with an extended opportunity to complete their physical share transfer processes that may have been incomplete due to various procedural or documentation issues encountered before the April 2019 deadline.

Natraj Proteins Limited has announced its financial results for the third quarter and nine months ended 31st December, 2025, showcasing a remarkable turnaround in profitability despite facing revenue headwinds. The agri-business company demonstrated strong operational efficiency improvements during the quarter.

Financial Performance Highlights

The company's quarterly performance showed significant improvement across key profitability metrics:

The company achieved a profit before tax of ₹290.13 lakhs in Q3FY26, compared to ₹5.15 lakhs in the corresponding quarter of the previous year, marking an exceptional improvement in operational performance.

Nine-Month Performance Analysis

For the nine-month period ended 31st December, 2025, Natraj Proteins demonstrated a complete turnaround from losses to profitability:

Cost Management and Operational Efficiency

The company's improved profitability was driven by effective cost management strategies. Cost of materials consumed decreased to ₹2094.36 lakhs in Q3FY26 from ₹2747.38 lakhs in Q3FY25. Total expenses for the quarter were ₹2591.2 lakhs compared to ₹3337.66 lakhs in the previous year, reflecting disciplined cost control measures.

Other income remained modest at ₹4.37 lakhs for the quarter, while finance costs increased to ₹59.36 lakhs from ₹50.11 lakhs year-on-year. Employee benefits expense decreased to ₹23.71 lakhs from ₹32.74 lakhs in the corresponding quarter.

Corporate Governance and Compliance

The Board of Directors meeting was held on 13th February, 2026, where the unaudited financial results were considered and approved. The results were also reviewed by the Audit Committee and received a limited review report from statutory auditors M/s Bhutoria Ganesan & Co. The company maintains a paid-up share capital of ₹374.7 lakhs with face value of ₹10 per share.

The financial results were prepared in compliance with Indian Accounting Standards (Ind AS) as notified under Section 133 of the Companies Act, 2013, ensuring adherence to regulatory requirements and transparency in financial reporting.